Roche’s House Advantage: Does Having It All Under One Roof Make A Difference?
The size of Roche’s pipeline and in-house diagnostics business are key advantages in oncology, top execs told the firm’s analyst meeting at ASCO. Roche’s oncology strategy includes replicating its HER2 success in hematology, targeting new pathways, entering immunotherapy and going all-in on antibody-drug conjugates.
You may also be interested in...
Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.